Erudio Healtherudio.com
Drug
Enfortumab vedotin trials: what clinicians said in public
An HCP commentary report on 1 clinical trial studying enfortumab vedotin: HCRN GU22-598. It covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 23 more trials with public commentary and no report yet.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| HCRN GU22-598 NCT06809140 · Matthew Galsky | muscle-invasive urothelial cancer of the bladder | Phase 2 | 173 | 11 | Standard | Nov 17, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| KEYNOTE-905 NCT03924895 · Merck Sharp & Dohme LLC DeepView → | cisplatin-ineligible muscle-invasive bladder cancer | Phase 3 | Deep | View | |||
| VOLGA NCT04960709 · AstraZeneca DeepView → | cisplatin-ineligible muscle-invasive bladder cancer | Phase 3 | Deep | View | |||
| KEYNOTE-B15 NCT04700124 · Merck Sharp & Dohme LLC DeepView → | cisplatin-eligible muscle-invasive bladder cancer | Phase 3 | Deep | View | |||
| EV-103 NCT03288545 · Astellas Pharma Global Development, Inc. DeepView → | urothelial cancer | Phase 1/Phase 2 | Deep | View | |||
| EV-301 NCT03474107 · Astellas Pharma Global Development, Inc. DeepView → | previously treated locally advanced or metastatic urothelial cancer | Phase 3 | Deep | View | |||
| TROPHY-U-01 NCT03547973 · Gilead Sciences DeepView → | unresectable locally advanced or metastatic urothelial cancer | Phase 2 | Deep | View | |||
| EV-201 NCT03219333 · Astellas Pharma Inc DeepView → | locally advanced or metastatic urothelial cancer | Phase 2 | Deep | View | |||
| EV-209 NCT07475806 · Astellas Pharma Global Development, Inc. DeepView → | muscle-invasive bladder cancer | Phase 2 | Deep | View | |||
| EV-309 NCT07566156 · Astellas Pharma Global Development, Inc. DeepView → | muscle-invasive bladder cancer | Phase 3 | Deep | View | |||
| EV-302 NCT04223856 · Astellas Pharma Global Development, Inc. DeepView → | untreated locally advanced or metastatic urothelial cancer | Phase 3 | Deep | View | |||
| EV-202 NCT04225117 · Astellas Pharma Global Development, Inc. DeepView → | locally advanced or metastatic malignant solid tumors | Phase 2 | Deep | View | |||
| FORAGER-1 NCT05614739 · Eli Lilly and Company DeepView → | advanced solid tumors with FGFR3 alterations | Phase 1 | Deep | View | |||
| INTerpath-005 NCT06305767 · Merck Sharp & Dohme LLC DeepView → | muscle-invasive urothelial carcinoma | Phase 1/Phase 2 | Deep | View | |||
| STAR-EV NCT06394570 · University of Texas Southwestern Medical Center StandardView → | localized bladder cancer | Phase 1/Phase 2 | Standard | View | |||
| EV-104 NCT05014139 · Astellas Pharma Global Development, Inc. StandardView → | non-muscle invasive bladder cancer | Phase 1 | Standard | View | |||
| MORPHEUS-UC NCT03869190 · Hoffmann-La Roche StandardView → | urothelial carcinoma | Phase 1/Phase 2 | Standard | View | |||
| E-VIRTUE NCT06041503 · National Cancer Institute (NCI) FocusedView → | rare genitourinary tumors | Phase 2 | Focused | View | |||
| Symbiotic-GU-06 NCT07421700 · Pfizer FocusedView → | locally advanced or metastatic urothelial cancer | Phase 1/Phase 2 | Focused | View | |||
| IMPROEV NCT07221942 · Fox Chase Cancer Center FocusedView → | Not given | Phase 2 | Focused | View | |||
| NCT05756569 NCT05756569 · Emory University FocusedView → | Not given | Phase 2 | Focused | View | |||
| CAST-AI NCT06764095 · Mayo Clinic FocusedView → | locally advanced or metastatic urothelial carcinoma | Phase 4 | Focused | View | |||
| TROPION-Urothelial04 NCT07720284 · AstraZeneca FocusedView → | Not given | Phase 3 | Focused | View | |||
| RETAIN-3 NCT07908979 · Fox Chase Cancer Center FocusedView → | muscle-invasive bladder urothelial carcinoma | Phase 2 | Focused | View | |||